Back to results
US 7,605,133 B2Granted
Isolated peptides to treat alpha-synuclein diseases
AssigneePanacea Pharmaceuticals, Inc.
InventorsBenjamin Wolozin, Natalie Ostretova-Golts, Michael S. Lebowitz
Life of this patent
Estimating the term…
Abstract
The present invention relates to drug screening methods and methods of preventing neural tissue damage caused by α-synuclein aggregation. These methods are especially useful in the design and development of inhibitors of Lewy body diseases and other synucleinopathies, and further useful in the treatment of such neurodegenerative diseases, particularly Parkinson's Disease.
Claims12
An isolated peptide that will bind to α-synuclein and inhibit aggregation of α-synuclein, said peptide consisting of a sequence selected from:
- WRQTRKD (SEQ ID NO:1);
- HYAKNPI (SEQ ID NO:2);
- ATINKSL (SEQ ID NO:3);
- RRRGMAI (SEQ ID NO:4);
- TKHGPRK (SEQ ID NO:6);
- SLKRLPK (SEQ ID NO:7);
- RLRGRNQ (SEQ ID NO:8);
- WPFHHHR (SEQ ID NO:9);
- HLYHHKT (SEQ ID NO:10);
- THIHHPS (SEQ ID NO:11);
- or MMMMMRL (SEQ ID NO:
- 12).
9 more elements
Dependencies are inferred from the claim text.